Literature DB >> 20824036

Mammography Screening and Treatment of Breast Cancer in the Elderly.

Matti Aapro1.   

Abstract

Breast cancer patients of an advanced age will suffer from ailments related to both senescence and cancer. Some will have been denied access to screening programmes and will present with an advanced disease. Many will need the expertise of the geriatrician and the oncologist who will participate in specific case discussions to look at social and medical issues that will affect the treatment plan (with questions regarding surgery, radiation, drug therapy, rehabilitation, supportive care, and palliative care often intertwined). This paper reviews recommendations by the International Society of Geriatric Oncology (SIOG) task force which recently assessed the available evidence on breast cancer in elderly individuals, and provided evidence-based recommendations for the diagnosis and treatment of breast cancer in such individuals. Recommendations on the topics of screening, surgery, radiotherapy, (neo)adjuvant hormone treatment, and chemotherapy, and on metastatic disease have been given. Oncologists are now learning to take into account the physiological age of their patient, which is the reflection of a normal and sometimes abnormally accelerated loss of body reserves which is certainly related to chronological age but not precisely dictated by it. Understanding the biology of breast cancer will allow to optimally adapt the treatment of the elderly patient.

Entities:  

Year:  2008        PMID: 20824036      PMCID: PMC2931114          DOI: 10.1159/000137627

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  31 in total

Review 1.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.

Authors:  M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

2.  Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.

Authors:  D Crivellari; M Bonetti; M Castiglione-Gertsch; R D Gelber; C M Rudenstam; B Thürlimann; K N Price; A S Coates; C Hürny; J Bernhard; J Lindtner; J Collins; H J Senn; F Cavalli; J Forbes; A Gudgeon; E Simoncini; H Cortes-Funes; A Veronesi; M Fey; A Goldhirsch
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

3.  Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

Authors:  Stephen E Jones; Michael A Savin; Frankie Ann Holmes; Joyce A O'Shaughnessy; Joanne L Blum; Svetislava Vukelja; Kristi J McIntyre; John E Pippen; James H Bordelon; Robert Kirby; John Sandbach; William J Hyman; Pankaj Khandelwal; Angel G Negron; Donald A Richards; Stephen P Anthony; Robert G Mennel; Kristi A Boehm; Walter G Meyer; Lina Asmar
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

4.  Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes.

Authors:  J Ragaz; A Coldman
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

5.  Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients.

Authors:  Roberto Gennari; Giuseppe Curigliano; Nicole Rotmensz; Chris Robertson; Marco Colleoni; Stefano Zurrida; Franco Nolè; Filippo de Braud; Laura Orlando; Maria Cristina Leonardi; Viviana Galimberti; Mattia Intra; Paolo Veronesi; Giuseppe Renne; Saverio Cinieri; Riccardo A Audisio; Alberto Luini; Roberto Orecchia; Giuseppe Viale; Aron Goldhirsch
Journal:  Cancer       Date:  2004-09-15       Impact factor: 6.860

6.  Undertreatment strongly decreases prognosis of breast cancer in elderly women.

Authors:  Christine Bouchardy; Elisabetta Rapiti; Gérald Fioretta; Paul Laissue; Isabelle Neyroud-Caspar; Peter Schäfer; John Kurtz; André-Pascal Sappino; Georges Vlastos
Journal:  J Clin Oncol       Date:  2003-08-11       Impact factor: 44.544

7.  Practical guidance for the management of aromatase inhibitor-associated bone loss.

Authors:  P Hadji; J-J Body; M S Aapro; A Brufsky; R E Coleman; T Guise; A Lipton; M Tubiana-Hulin
Journal:  Ann Oncol       Date:  2008-04-29       Impact factor: 32.976

8.  Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.

Authors:  Hyman B Muss; Dongsheng Tu; James N Ingle; Silvana Martino; Nicholas J Robert; Joseph L Pater; Timothy J Whelan; Michael J Palmer; Martine J Piccart; Lois E Shepherd; Kathleen I Pritchard; Zhi He; Paul E Goss
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544

Review 9.  Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.

Authors:  M Aapro; P A Abrahamsson; J J Body; R E Coleman; R Colomer; L Costa; L Crinò; L Dirix; M Gnant; J Gralow; P Hadji; G N Hortobagyi; W Jonat; A Lipton; A Monnier; A H G Paterson; R Rizzoli; F Saad; B Thürlimann
Journal:  Ann Oncol       Date:  2007-09-28       Impact factor: 32.976

10.  Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study.

Authors:  Yvonne Wengström; Matti Aapro; Susanna Leto di Priolo; Helena Cannon; Vasoulla Georgiou
Journal:  Breast       Date:  2007-04-20       Impact factor: 4.380

View more
  1 in total

1.  Breast Cancer in Special Situations.

Authors:  Bernd Gerber
Journal:  Breast Care (Basel)       Date:  2008-06-19       Impact factor: 2.860

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.